Dhaval Patel

Dhaval Patel currently serves as the Executive Vice President and Chief Scientific Officer at Sana Biotechnology, Inc. and holds various leadership roles including Chair of the Board of Directors at MIMETAS and Non-Executive Director positions at Priothera SAS, Quell Therapeutics, and Anokion. Additionally, Dhaval Patel has had a long-standing academic career at the University of North Carolina at Chapel Hill, where titles include Clinical Professor, Eminent Professor of Medicine, Director of the Thurston Arthritis Research Center, Chief of the Division of Rheumatology, Allergy and Immunology, and Professor in the Department of Microbiology and Immunology. Previous experience includes serving as Executive Vice President and Chief Scientific Officer at UCB, Non-Executive Director roles at Inflazome Ltd, and Kanyos Bio, as well as an Entrepreneur in Residence at the Novartis Venture Fund. Educational credentials include a Doctor of Philosophy (PhD) in Microbiology and Immunology and a Doctor of Medicine (MD) from Duke University, where a Bachelor of Science (BS) degree was also earned, graduated summa cum laude in Zoology/Animal Biology.